-- Adherium Limited (ASX: ADR), a leader in digital health technologies, is pleased to announce it has commenced production and market release of its advanced Hailie® Smartinhaler® connecting Teva Pharmaceutical Industries Ltd. (Teva) available authorized generic option of ProAir® HFA Albuterol Sulphate pressurised metered dose inhalers (pMDIs) with its new, next generation sensor capturing physiological data such as inhalation flow rate.
This advanced digital sensor further supports respiratory-focused hospitals, medical groups and payors to actively manage respiratory disease for improved health outcomes, enabling reimbursement, and saving healthcare costs through remote patient monitoring.
Adherium is currently working with its initial large scale strategic partners, Allergy Partners and SENTA, to enroll patients on its Hailie platform using its range of US FDA 510(k) cleared Smartinhalers to generate and transmit the data enabling remote patient monitoring reimbursement. The production and sale of the Hailie platform underpins Adherium reaching a cash flow positive position.
Now achieving four market release milestones of the next generation Hailie Smartinhalers, Adherium progressed on its commercial strategy to 79% market coverage for sensors capturing physiological data such as inhalation flow rate, and 91% market coverage for adherence tracking of US top 20 branded inhaler medications by sales volume. Hailie Smartinhalers are the only FDA 510(k) cleared drug agnostic sensor available today to offer physiological data insights on inhaler technique.
Francis White, Vice President of Global Business Development at Adherium, states: “We are pleased to be able to provide access to Hailie Smartinhalers to tens of thousands of patients through our growing partnerships with US respiratory hospital and medical group systems, equipping patients with the most advanced tools to manage their respiratory health and vastly improve their quality of life.”
